{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:19Z","timestamp":1792783459472,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-028"],"award-info":[{"award-number":["2022-PUMCH-C-028"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2024-I2M-C&T-B-009"],"award-info":[{"award-number":["2024-I2M-C&T-B-009"]}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["3332024131"],"award-info":[{"award-number":["3332024131"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s42000-026-00792-1","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:12:06Z","timestamp":1780416726000},"page":"399-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multi-omics insights into metastatic pheochromocytomas and paragangliomas: Mechanisms, signatures, and prediction models"],"prefix":"10.1007","volume":"25","author":[{"given":"Yue","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1418-1012","authenticated-orcid":false,"given":"Anli","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"792_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","volume":"43","author":"S N\u00f6lting","year":"2022","unstructured":"N\u00f6lting S, Bechmann N, Taieb D et al (2022) Personalized management of pheochromocytoma and paraganglioma. Endocr Rev 43:199\u2013239. https:\/\/doi.org\/10.1210\/endrev\/bnab019","journal-title":"Endocr Rev"},{"key":"792_CR2","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1210\/jc.2018-01968","volume":"104","author":"S Hescot","year":"2019","unstructured":"Hescot S, Curras-Freixes M, Deutschbein T et al (2019) Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European Network for the Study of Adrenal Tumors retrospective study. J Clin Endocrinol Metab 104:2367\u20132374. https:\/\/doi.org\/10.1210\/jc.2018-01968","journal-title":"J Clin Endocrinol Metab"},{"key":"792_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","volume":"33","author":"D Wu","year":"2009","unstructured":"Wu D, Tischler AS, Lloyd RV et al (2009) Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol 33:599\u2013608. https:\/\/doi.org\/10.1097\/PAS.0b013e318190d12e","journal-title":"Am J Surg Pathol"},{"key":"792_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","volume":"26","author":"LD Thompson","year":"2002","unstructured":"Thompson LD (2002) Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26:551\u2013566. https:\/\/doi.org\/10.1097\/00000478-200205000-00002","journal-title":"Am J Surg Pathol"},{"key":"792_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/erc-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"Kimura N, Takayanagi R, Takizawa N et al (2014) Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21:405\u2013414. https:\/\/doi.org\/10.1530\/erc-13-0494","journal-title":"Endocr Relat Cancer"},{"key":"792_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.surg.2018.05.001","volume":"164","author":"YY Cho","year":"2018","unstructured":"Cho YY, Kwak MK, Lee SE et al (2018) A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score. Surgery 164:511\u2013517. https:\/\/doi.org\/10.1016\/j.surg.2018.05.001","journal-title":"Surgery"},{"key":"792_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","volume":"474","author":"C Pierre","year":"2019","unstructured":"Pierre C, Agopiantz M, Brunaud L et al (2019) COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas. Virchows Arch 474:721\u2013734. https:\/\/doi.org\/10.1007\/s00428-019-02553-5","journal-title":"Virchows Arch"},{"key":"792_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, Asa SL, Gill AJ et al (2022) Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 33:90\u2013114. https:\/\/doi.org\/10.1007\/s12022-022-09704-6","journal-title":"Endocr Pathol"},{"key":"792_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","volume":"14","author":"B Calsina","year":"2023","unstructured":"Calsina B, Pi\u00f1eiro-Y\u00e1\u00f1ez E, Mart\u00ednez-Montes \u00c1M et al (2023) Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma. Nat Commun 14:1122. https:\/\/doi.org\/10.1038\/s41467-023-36769-6","journal-title":"Nat Commun"},{"key":"792_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1530\/eje-20-1407","volume":"185","author":"M Murakami","year":"2021","unstructured":"Murakami M, Sun N, Greunke C et al (2021) Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma. Eur J Endocrinol 185:179\u2013191. https:\/\/doi.org\/10.1530\/eje-20-1407","journal-title":"Eur J Endocrinol"},{"key":"792_CR11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae797","author":"T Drossart","year":"2024","unstructured":"Drossart T, Buffet A, Janbain A et al (2024) Biomarkers improving genetic and metastatic disease prediction in paraganglioma: insights from a prospective study. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae797","journal-title":"J Clin Endocrinol Metab"},{"key":"792_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"792_CR13","doi-asserted-by":"publisher","first-page":"e082505","DOI":"10.1136\/bmj-2024-082505","volume":"388","author":"KGM Moons","year":"2025","unstructured":"Moons KGM, Damen JAA, Kaul T et al (2025) PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods. BMJ 388:e082505. https:\/\/doi.org\/10.1136\/bmj-2024-082505","journal-title":"BMJ"},{"key":"792_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Leshchiner I, Walter V et al (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31:181\u2013193. https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001","journal-title":"Cancer Cell"},{"key":"792_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1210\/clinem\/dgaf584","volume":"111","author":"LK Svendsen","year":"2026","unstructured":"Svendsen LK, Rasmussen \u00c5K, Klose MC et al (2026) Metastatic disease in phaeochromocytomas and paragangliomas in various genotypes-a systematic review and meta-analysis. J Clin Endocrinol Metab 111:580\u2013590. https:\/\/doi.org\/10.1210\/clinem\/dgaf584","journal-title":"J Clin Endocrinol Metab"},{"key":"792_CR16","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1016\/j.celrep.2020.03.022","volume":"30","author":"A Morin","year":"2020","unstructured":"Morin A, Goncalves J, Moog S et al (2020) TET-mediated hypermethylation primes SDH-deficient cells for HIF2\u03b1-driven mesenchymal transition. Cell Rep 30:4551-4566.e4557. https:\/\/doi.org\/10.1016\/j.celrep.2020.03.022","journal-title":"Cell Rep"},{"key":"792_CR17","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1158\/1078-0432.Ccr-07-1867","volume":"14","author":"J Geli","year":"2008","unstructured":"Geli J, Kiss N, Karimi M et al (2008) Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior. Clin Cancer Res 14:2551\u20132559. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-1867","journal-title":"Clin Cancer Res"},{"key":"792_CR18","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa2504964","volume":"393","author":"C Jimenez","year":"2025","unstructured":"Jimenez C, Andreassen M, Durand A et al (2025) Belzutifan for advanced pheochromocytoma or paraganglioma. N Engl J Med 393:2012\u20132022. https:\/\/doi.org\/10.1056\/NEJMoa2504964","journal-title":"N Engl J Med"},{"key":"792_CR19","doi-asserted-by":"publisher","unstructured":"Liu Y, Pang Y, Caisova V et al (2020) Targeting NRF2-governed glutathione synthesis for SDHB-mutated Pheochromocytoma and Paraganglioma. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12020280","DOI":"10.3390\/cancers12020280"},{"key":"792_CR20","doi-asserted-by":"publisher","unstructured":"Sarkadi B, Meszaros K, Krencz I et al (2020) Glutaminases as a novel target for SDHB-associated Pheochromocytomas\/Paragangliomas. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12030599","DOI":"10.3390\/cancers12030599"},{"key":"792_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12020-022-03218-1","volume":"79","author":"S Ghosal","year":"2023","unstructured":"Ghosal S, Hadrava Vanova K, Uher O et al (2023) Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis. Endocrine 79:171\u2013179. https:\/\/doi.org\/10.1007\/s12020-022-03218-1","journal-title":"Endocrine"},{"key":"792_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/path.6026","volume":"259","author":"L Celada","year":"2023","unstructured":"Celada L, Cubiella T, San-Juan-Guardado J et al (2023) Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype. J Pathol 259:103\u2013114. https:\/\/doi.org\/10.1002\/path.6026","journal-title":"J Pathol"},{"key":"792_CR23","doi-asserted-by":"publisher","first-page":"111193","DOI":"10.1016\/j.celrep.2022.111193","volume":"40","author":"N Gudgeon","year":"2022","unstructured":"Gudgeon N, Munford H, Bishop EL et al (2022) Succinate uptake by T cells suppresses their effector function via inhibition of mitochondrial glucose oxidation. Cell Rep 40:111193. https:\/\/doi.org\/10.1016\/j.celrep.2022.111193","journal-title":"Cell Rep"},{"key":"792_CR24","doi-asserted-by":"publisher","first-page":"589451","DOI":"10.3389\/fendo.2021.589451","volume":"12","author":"DM Matlac","year":"2021","unstructured":"Matlac DM, Hadrava Vanova K, Bechmann N et al (2021) Succinate mediates tumorigenic effects via Succinate Receptor 1: potential for new targeted treatment strategies in Succinate Dehydrogenase deficient paragangliomas. Front Endocrinol (Lausanne) 12:589451. https:\/\/doi.org\/10.3389\/fendo.2021.589451","journal-title":"Front Endocrinol (Lausanne)"},{"key":"792_CR25","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","volume":"23","author":"LJ Castro-Vega","year":"2014","unstructured":"Castro-Vega LJ, Buffet A, De Cubas AA et al (2014) Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet 23:2440\u20132446. https:\/\/doi.org\/10.1093\/hmg\/ddt639","journal-title":"Hum Mol Genet"},{"key":"792_CR26","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1158\/0008-5472.Can-17-2463","volume":"78","author":"A Buffet","year":"2018","unstructured":"Buffet A, Morin A, Castro-Vega LJ et al (2018) Germline mutations in the mitochondrial 2-Oxoglutarate\/Malate Carrier SLC25A11 gene confer a predisposition to metastatic paragangliomas. Cancer Res 78:1914\u20131922. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-2463","journal-title":"Cancer Res"},{"key":"792_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/erc-20-0205","volume":"27","author":"N Bechmann","year":"2020","unstructured":"Bechmann N, Moskopp ML, Ullrich M et al (2020) HIF2\u03b1 supports pro-metastatic behavior in pheochromocytomas\/paragangliomas. Endocr Relat Cancer 27:625\u2013640. https:\/\/doi.org\/10.1530\/erc-20-0205","journal-title":"Endocr Relat Cancer"},{"key":"792_CR28","doi-asserted-by":"publisher","first-page":"11588","DOI":"10.1038\/s41598-023-38606-8","volume":"13","author":"S Karakaya","year":"2023","unstructured":"Karakaya S, Gunnesson L, Elias E et al (2023) Cytoplasmic HIF-2\u03b1 as tissue biomarker to identify metastatic sympathetic paraganglioma. Sci Rep 13:11588. https:\/\/doi.org\/10.1038\/s41598-023-38606-8","journal-title":"Sci Rep"},{"key":"792_CR29","doi-asserted-by":"publisher","first-page":"6262","DOI":"10.1038\/s41467-022-34011-3","volume":"13","author":"M Zethoven","year":"2022","unstructured":"Zethoven M, Martelotto L, Pattison A et al (2022) Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment. Nat Commun 13:6262. https:\/\/doi.org\/10.1038\/s41467-022-34011-3","journal-title":"Nat Commun"},{"key":"792_CR30","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1158\/1541-7786.Mcr-20-0992","volume":"19","author":"N Alzofon","year":"2021","unstructured":"Alzofon N, Koc K, Panwell K et al (2021) Mastermind like transcriptional coactivator 3 (MAML3) drives neuroendocrine tumor progression. Mol Cancer Res 19:1476\u20131485. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-20-0992","journal-title":"Mol Cancer Res"},{"key":"792_CR31","doi-asserted-by":"publisher","first-page":"101931","DOI":"10.1016\/j.beem.2024.101931","volume":"38","author":"M Monteagudo","year":"2024","unstructured":"Monteagudo M, Calsina B, Salazar-Hidalgo ME et al (2024) MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab 38:101931. https:\/\/doi.org\/10.1016\/j.beem.2024.101931","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"792_CR32","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/1078-0432.Ccr-18-0139","volume":"25","author":"S Job","year":"2019","unstructured":"Job S, Draskovic I, Burnichon N et al (2019) Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 25:760\u2013770. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0139","journal-title":"Clin Cancer Res"},{"key":"792_CR33","doi-asserted-by":"publisher","unstructured":"Flynn A, Pattison AD, Balachander S et al (2024) Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-4410500\/v1","DOI":"10.21203\/rs.3.rs-4410500\/v1"},{"key":"792_CR34","doi-asserted-by":"publisher","unstructured":"Monteagudo M, Mart\u00ednez P, Leandro-Garc\u00eda LJ et al (2021) Analysis of telomere maintenance related genes reveals NOP10 as a new metastatic-risk marker in Pheochromocytoma\/Paraganglioma. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13194758","DOI":"10.3390\/cancers13194758"},{"key":"792_CR35","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, Li H, Zhang L et al (2025) Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res 53:D1670-d1676. https:\/\/doi.org\/10.1093\/nar\/gkae973","journal-title":"Nucleic Acids Res"},{"key":"792_CR36","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1158\/1078-0432.Ccr-14-2804","volume":"21","author":"AA de Cubas","year":"2015","unstructured":"de Cubas AA, Korpershoek E, Inglada-P\u00e9rez L et al (2015) DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers. Clin Cancer Res 21:3020\u20133030. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2804","journal-title":"Clin Cancer Res"},{"key":"792_CR37","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1210\/jc.2018-01471","volume":"104","author":"C Bernardo-Casti\u00f1eira","year":"2019","unstructured":"Bernardo-Casti\u00f1eira C, Vald\u00e9s N, Celada L et al (2019) Epigenetic deregulation of protocadherin PCDHGC3 in pheochromocytomas\/paragangliomas associated with SDHB mutations. J Clin Endocrinol Metab 104:5673\u20135692. https:\/\/doi.org\/10.1210\/jc.2018-01471","journal-title":"J Clin Endocrinol Metab"},{"key":"792_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1530\/erc-11-0308","volume":"19","author":"E Patterson","year":"2012","unstructured":"Patterson E, Webb R, Weisbrod A et al (2012) The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer 19:157\u2013166. https:\/\/doi.org\/10.1530\/erc-11-0308","journal-title":"Endocr Relat Cancer"},{"key":"792_CR39","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1002\/ctm2.260","volume":"10","author":"LJ Castro-Vega","year":"2020","unstructured":"Castro-Vega LJ, Calsina B, Burnichon N et al (2020) Overexpression of miR-483-5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma\/paraganglioma. Clin Transl Med 10:e260. https:\/\/doi.org\/10.1002\/ctm2.260","journal-title":"Clin Transl Med"},{"key":"792_CR40","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.7150\/thno.35458","volume":"9","author":"B Calsina","year":"2019","unstructured":"Calsina B, Castro-Vega LJ, Torres-P\u00e9rez R et al (2019) Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p\/TSC2\/mTOR axis in metastatic pheochromocytoma\/paraganglioma. Theranostics 9:4946\u20134958. https:\/\/doi.org\/10.7150\/thno.35458","journal-title":"Theranostics"},{"key":"792_CR41","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1677\/erc-10-0142","volume":"17","author":"GY Meyer-Rochow","year":"2010","unstructured":"Meyer-Rochow GY, Jackson NE, Conaglen JV et al (2010) MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer 17:835\u2013846. https:\/\/doi.org\/10.1677\/erc-10-0142","journal-title":"Endocr Relat Cancer"},{"key":"792_CR42","first-page":"1545","volume":"8","author":"L Zong","year":"2015","unstructured":"Zong L, Meng L, Shi R (2015) Role of miR-101 in pheochromocytoma patients with SDHD mutation. Int J Clin Exp Pathol 8:1545\u20131554","journal-title":"Int J Clin Exp Pathol"},{"key":"792_CR43","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12020-010-9422-5","volume":"39","author":"A Szalat","year":"2011","unstructured":"Szalat A, Fraenkel M, Doviner V et al (2011) Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine 39:160\u2013166. https:\/\/doi.org\/10.1007\/s12020-010-9422-5","journal-title":"Endocrine"},{"key":"792_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1530\/jme-11-0077","volume":"48","author":"J Guillemot","year":"2012","unstructured":"Guillemot J, Thou\u00ebnnon E, Gu\u00e9rin M et al (2012) Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66. J Mol Endocrinol 48:115\u2013127. https:\/\/doi.org\/10.1530\/jme-11-0077","journal-title":"J Mol Endocrinol"},{"key":"792_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1677\/erc.1.00913","volume":"12","author":"FM Brouwers","year":"2005","unstructured":"Brouwers FM, Petricoin EF 3rd, Ksinantova L (2005) Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer 12:263\u2013272. https:\/\/doi.org\/10.1677\/erc.1.00913","journal-title":"Endocr Relat Cancer"},{"key":"792_CR46","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1210\/endrev\/bnad011","volume":"44","author":"G Eisenhofer","year":"2023","unstructured":"Eisenhofer G, Pamporaki C, Lenders JWM (2023) Biochemical assessment of pheochromocytoma and paraganglioma. Endocr Rev 44:862\u2013909. https:\/\/doi.org\/10.1210\/endrev\/bnad011","journal-title":"Endocr Rev"},{"key":"792_CR47","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","volume":"48","author":"G Eisenhofer","year":"2012","unstructured":"Eisenhofer G, Lenders JW, Siegert G et al (2012) Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 48:1739\u20131749. https:\/\/doi.org\/10.1016\/j.ejca.2011.07.016","journal-title":"Eur J Cancer"},{"key":"792_CR48","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/s2589-7500(23)00094-8","volume":"5","author":"C Pamporaki","year":"2023","unstructured":"Pamporaki C, Berends AMA, Filippatos A et al (2023) Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort. Lancet Digit Health 5:e551\u2013e559. https:\/\/doi.org\/10.1016\/s2589-7500(23)00094-8","journal-title":"Lancet Digit Health"},{"key":"792_CR49","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/joim.13791","volume":"296","author":"SS Park","year":"2024","unstructured":"Park SS, Ahn CH, Lee S et al (2024) Preoperative prediction of metastatic pheochromocytoma and paraganglioma using clinical, genetic, and biochemical markers: a cohort study. J Intern Med 296:68\u201379. https:\/\/doi.org\/10.1111\/joim.13791","journal-title":"J Intern Med"},{"key":"792_CR50","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1210\/jc.2014-2151","volume":"99","author":"S Richter","year":"2014","unstructured":"Richter S, Peitzsch M, Rapizzi E et al (2014) Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas\/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab 99:3903\u20133911. https:\/\/doi.org\/10.1210\/jc.2014-2151","journal-title":"J Clin Endocrinol Metab"},{"key":"792_CR51","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1530\/erc-22-0020","volume":"29","author":"N Tufton","year":"2022","unstructured":"Tufton N, Hearnden RJ, Berney DM et al (2022) The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas. Endocr Relat Cancer 29:589\u2013598. https:\/\/doi.org\/10.1530\/erc-22-0020","journal-title":"Endocr Relat Cancer"},{"key":"792_CR52","doi-asserted-by":"publisher","first-page":"587779","DOI":"10.3389\/fendo.2020.587779","volume":"11","author":"X Gao","year":"2020","unstructured":"Gao X, Yamazaki Y, Pecori A et al (2020) Histopathological analysis of tumor microenvironment and angiogenesis in pheochromocytoma. Front Endocrinol (Lausanne) 11:587779. https:\/\/doi.org\/10.3389\/fendo.2020.587779","journal-title":"Front Endocrinol (Lausanne)"},{"key":"792_CR53","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1210\/clinem\/dgae702","volume":"110","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Zhang W, Cui Y et al (2025) Alterations and clinical value of peripheral lymphocyte subsets and inflammatory factors in paragangliomas. J Clin Endocrinol Metab 110:1952\u20131963. https:\/\/doi.org\/10.1210\/clinem\/dgae702","journal-title":"J Clin Endocrinol Metab"},{"key":"792_CR54","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1210\/clinem\/dgad149","volume":"108","author":"X Zhong","year":"2023","unstructured":"Zhong X, Su T, Yang Y et al (2023) Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic markers for pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 108:2230\u20132239. https:\/\/doi.org\/10.1210\/clinem\/dgad149","journal-title":"J Clin Endocrinol Metab"},{"key":"792_CR55","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/ejcts\/ezz115","volume":"56","author":"YR Hsu","year":"2019","unstructured":"Hsu YR, Torres-Mora J, Kipp BR et al (2019) Clinicopathological, immunophenotypic and genetic studies of mediastinal paragangliomas\u2020. Eur J Cardiothorac Surg 56:867\u2013875. https:\/\/doi.org\/10.1093\/ejcts\/ezz115","journal-title":"Eur J Cardiothorac Surg"},{"key":"792_CR56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.humpath.2018.10.041","volume":"86","author":"D Guo","year":"2019","unstructured":"Guo D, Zhao X, Wang A et al (2019) PD-L1 expression and association with malignant behavior in pheochromocytomas\/paragangliomas. Hum Pathol 86:155\u2013162. https:\/\/doi.org\/10.1016\/j.humpath.2018.10.041","journal-title":"Hum Pathol"},{"key":"792_CR57","doi-asserted-by":"publisher","first-page":"e1358332","DOI":"10.1080\/2162402x.2017.1358332","volume":"6","author":"DJ Pinato","year":"2017","unstructured":"Pinato DJ, Black JR, Trousil S et al (2017) Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: relationship with the hypoxic response, immune evasion and malignant behavior. Oncoimmunology 6:e1358332. https:\/\/doi.org\/10.1080\/2162402x.2017.1358332","journal-title":"Oncoimmunology"},{"key":"792_CR58","doi-asserted-by":"publisher","unstructured":"Uher O, Huynh TT, Zhu B et al (2021) Identification of immune cell infiltration in murine pheochromocytoma during combined mannan-BAM, TLR Ligand, and anti-CD40 antibody-based immunotherapy. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13163942","DOI":"10.3390\/cancers13163942"},{"key":"792_CR59","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12022-020-09632-3","volume":"31","author":"YY Zhou","year":"2020","unstructured":"Zhou YY, Coffey M, Mansur D et al (2020) Images in endocrine pathology: progressive loss of sustentacular cells in a case of recurrent jugulotympanic paraganglioma over a span of 5 years. Endocr Pathol 31:310\u2013314. https:\/\/doi.org\/10.1007\/s12022-020-09632-3","journal-title":"Endocr Pathol"},{"key":"792_CR60","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s40618-022-01826-2","volume":"45","author":"A De Leo","year":"2022","unstructured":"De Leo A, Vara G, Paccapelo A et al (2022) Computerized tomography texture analysis of pheochromocytoma: relationship with hormonal and histopathological data. J Endocrinol Invest 45:1935\u20131944. https:\/\/doi.org\/10.1007\/s40618-022-01826-2","journal-title":"J Endocrinol Invest"},{"key":"792_CR61","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.acra.2024.01.008","volume":"31","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhan Y, Zhao J et al (2024) CT-based radiomics analysis of different machine learning models for discriminating the risk stratification of pheochromocytoma and paraganglioma: a multicenter study. Acad Radiol 31:2859\u20132871. https:\/\/doi.org\/10.1016\/j.acra.2024.01.008","journal-title":"Acad Radiol"},{"key":"792_CR62","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00261-024-04279-8","volume":"49","author":"J Zhao","year":"2024","unstructured":"Zhao J, Zhan Y, Zhou Y et al (2024) CT-based radiomics research for discriminating the risk stratification of pheochromocytoma using different machine learning models: a multi-center study. Abdom Radiol (NY) 49:1569\u20131583. https:\/\/doi.org\/10.1007\/s00261-024-04279-8","journal-title":"Abdom Radiol (NY)"},{"key":"792_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13244-025-01952-4","volume":"16","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Zhan Y, Zhao J et al (2025) CT-based radiomics deep learning signatures for non-invasive prediction of metastatic potential in pheochromocytoma and paraganglioma: a multicohort study. Insights Imaging 16:81. https:\/\/doi.org\/10.1186\/s13244-025-01952-4","journal-title":"Insights Imaging"},{"issue":"1","key":"792_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1385\/EP:16:1:023","volume":"16","author":"N Kimura","year":"2005","unstructured":"Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y (2005) Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16(1):23\u201332","journal-title":"Endocr Pathol"},{"issue":"2","key":"792_CR65","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.urology.2006.02.019","volume":"68","author":"B Gao","year":"2006","unstructured":"Gao B, Meng F, Bian W, Chen J, Zhao H, Ma G et al (2006) Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology 68(2):282\u2013286","journal-title":"Urology"},{"key":"792_CR66","doi-asserted-by":"publisher","first-page":"e0187398","DOI":"10.1371\/journal.pone.0187398","volume":"12","author":"JM Koh","year":"2017","unstructured":"Koh JM, Ahn SH, Kim H et al (2017) Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS ONE 12:e0187398. https:\/\/doi.org\/10.1371\/journal.pone.0187398","journal-title":"PLoS ONE"},{"issue":"2","key":"792_CR67","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/cen.13357","volume":"87","author":"X Zhong","year":"2017","unstructured":"Zhong X, Ye L, Su T, Xie J, Zhou W, Jiang Y et al (2017) Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) 87(2):127\u2013135","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"792_CR68","first-page":"1540","volume":"23","author":"C Nastos","year":"2018","unstructured":"Nastos C, Yiallourou A, Kotsis T, Mizamtsidi M, Delaportas D, Kondi-Pafiti A et al (2018) Immunohistochemical expression patterns of S100, synaptophysin, chromogranin A and neuron specific enolase in predicting malignant behaviour in paragangliomas. J BUON\u202f: Off J Balkan Union Oncol 23(5):1540\u20131545","journal-title":"J BUON : Off J Balkan Union Oncol"},{"key":"792_CR69","doi-asserted-by":"publisher","first-page":"1235243","DOI":"10.3389\/fendo.2023.1235243","volume":"14","author":"H Hanschell","year":"2023","unstructured":"Hanschell H, Diaz-Cano S, Blanes A, Talat N, Galat\u00e1 G, Aylwin S et al (2023) Lesion-based indicators predict long-term outcomes of pheochromocytoma and paraganglioma\u2013 SIZEPASS. Front Endocrinol 14:1235243","journal-title":"Front Endocrinol"},{"key":"792_CR70","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40618-023-02239-5","volume":"47","author":"Y Cui","year":"2024","unstructured":"Cui Y, Zhou Y, Gao Y et al (2024) Novel alternative tools for metastatic pheochromocytomas\/paragangliomas prediction. J Endocrinol Invest 47:1191\u20131203. https:\/\/doi.org\/10.1007\/s40618-023-02239-5","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"792_CR71","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1210\/clinem\/dgae797","volume":"110","author":"T Drossart","year":"2025","unstructured":"Drossart T, Buffet A, Janbain A, Ottolenghi C, Amar L, Lib\u00e9 R et al (2025) Biomarkers improving genetic and metastatic disease prediction in Paraganglioma: insights from a prospective study. J Clin Endocrinol Metab 110(8):2193\u20132204","journal-title":"J Clin Endocrinol Metab"},{"key":"792_CR72","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/jso.27653","volume":"129","author":"YL Oh","year":"2024","unstructured":"Oh YL, Byeon SJ, Suh YJ (2024) Prediction model for pheochromocytoma\/paraganglioma using nCounter assay. J Surg Oncol 129:1481\u20131489. https:\/\/doi.org\/10.1002\/jso.27653","journal-title":"J Surg Oncol"},{"key":"792_CR73","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Barcel\u00f3 C, Gil D, Tom\u00e1s D, Bernabeu D (2025) Prediction of metastasis in paragangliomas and pheochromocytomas using machine learning models: Explainability challenges. Sensors (Basel) 25. https:\/\/doi.org\/10.3390\/s25134184","DOI":"10.3390\/s25134184"},{"key":"792_CR74","doi-asserted-by":"publisher","unstructured":"Stenman A, Zedenius J, Juhlin CC (2019) The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal Paragangliomas-A meta-analysis and systematic review of the literature. Cancers (Basel) 11. https:\/\/doi.org\/10.3390\/cancers11020225","DOI":"10.3390\/cancers11020225"},{"key":"792_CR75","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00423-018-1679-9","volume":"403","author":"A Stenman","year":"2018","unstructured":"Stenman A, Zedenius J, Juhlin CC (2018) Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms. Langenbecks Arch Surg 403:785\u2013790. https:\/\/doi.org\/10.1007\/s00423-018-1679-9","journal-title":"Langenbecks Arch Surg"},{"key":"792_CR76","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/pas.0000000000002238","volume":"48","author":"Q Li","year":"2024","unstructured":"Li Q, Lan Z, Jiang Y et al (2024) Validation and evaluation of 5 scoring systems for predicting metastatic risk in pheochromocytoma and paraganglioma. Am J Surg Pathol 48:855\u2013865. https:\/\/doi.org\/10.1097\/pas.0000000000002238","journal-title":"Am J Surg Pathol"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00792-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00792-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00792-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:31:46Z","timestamp":1789565506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-026-00792-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["792"],"URL":"https:\/\/doi.org\/10.1007\/s42000-026-00792-1","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest; we do not have any conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}